Engineering Papers⌕ Search

SEARCH · Engineering Papers

Results for “eclipse”

Search indexed NASA NTRS and DOE OSTI research on propulsion, heat transfer, battery materials and energy systems. Follow report and document links to the original sources.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21

SU-F-SPS-01: Accuracy of the Small Field Dosimetry Using Acuros XB and AAA Dose Calculation Algorithms of Eclipse Treatment Planning System Within and Beyond Heterogeneous Media for Trubeam 2.0 Unit

Purpose: In this study, the comparison of dosimetric accuracy of Acuros XB and AAA algorithms were investigated for small radiation fields incident on homogeneous and heterogeneous geometries Methods: Small open fields of Truebeam 2.0 unit (1×1, 2×2, 3×3, 4×4 fields) were used for this study. The fields were incident on homogeneous phantom and in house phantom containing lung, air, and bone inhomogeneities. Using the same film batch, the net OD to dose calibration curve was obtaine dusing Trubeam 2.0 for 6 MV, 6 FFF, 10 MV, 10 FFF, 15 MV energies by delivering 0- 800 cGy. Films were scanned 48 hours after irradiation using an Epson 1000XL flatbed scanner. The dosimetric accuracy of Acuros XB and AAA algorithms in the presence of the inhomogeneities was compared against EBT3 film dosimetry Results: Open field tests in a homogeneous phantom showed good agreement betweent wo algorithms and measurement. For Acuros XB, minimum gamma analysis passin grates between measured and calculated dose distributions were 99.3% and 98.1% for homogeneousand inhomogeneous fields in thecase of lung and bone respectively. For AAA, minimum gamma analysis passingrates were 99.1% and 96.5% for homogeneous and inhomogeneous fields respectively for all used energies and field sizes.In the case of the air heterogeneity, the differences were larger for both calculations algorithms. Over all, when compared to measurement, theAcuros XB had beter agreement than AAA. Conclusion: The Acuros XB calculation algorithm in the TPS is an improvemen tover theexisting AAA algorithm. Dose discrepancies were observed for in the presence of air inhomogeneities.

60 APPLIED LIFE SCIENCES↗

The Pre-He White Dwarfs in Eclipsing Binaries. II. WASP 0843–11

We present the Transiting Exoplanet Survey Satellite (TESS) photometry and our high-resolution spectra of the EL CVn–type star 1SWASP J084356.46–113327.5 (WASP 0843–11), which consists of an F-type main-sequence (MS) star and a hotter low-mass helium white dwarf precursor (pre-He WD). In a spectral analysis, double-lined radial velocities (RVs) were obtained for the first time. From a simultaneous analysis of the TESS light and RV curves, the masses, radii, and temperatures of each component were determined to be M {sub 1} = 1.733 ± 0.031 M {sub ⊙}, M {sub 2} = 0.220 ± 0.008 M {sub ⊙}, R {sub 1} = 2.094 ± 0.013 R {sub ⊙}, R {sub 2} = 0.331 ± 0.003 R {sub ⊙}, T {sub 1} = 6960 ± 120 K, and T {sub 2} =9870 ± 310 K, respectively. According to their physical properties, the primary and secondary stars are located on the instability strips of δ Sct/γ Dor hybrids and extremely low-mass WDs, respectively. We applied multiple frequency analyses to the residual light curve after subtracting the binarity effects and detected a total of four independent frequencies. A frequency of f {sub 3} = 1.6356 day{sup −1} in the low-frequency region was reminiscent of γ Dor stars, while the other three frequencies of f {sub 2}, f {sub 15}, and f {sub 18} in the high-frequency region (150–196 day{sup −1}) are probably related to pre-He WD components. Our results demonstrate that the more massive MS primary star of WASP 0843–11 is a γ Dor pulsator, whereas the hotter secondary component is a pre-He WD with high-frequency pulsations.

47 OTHER INSTRUMENTATION↗

Fundamental Parameters of the Eclipsing Binary DD CMa and Evidence for Mass Exchange

We present a detailed photometric and spectroscopic analysis of DD CMa, based on published survey photometry and new spectroscopic data. We find an improved orbital period of P {sub o} = 2.0084530(6) days. Our spectra reveal Hβ and Hα absorptions with weak emission shoulders, and we also find a color excess in the Wide-field Infrared Survey Explorer multiband photometry, interpreted as signatures of circumstellar matter. We model the V-band orbital light curve derived from the ASAS and ASAS-SN surveys, assuming a semidetached configuration and using the mass ratio and temperature of the hotter star derived from our spectroscopic analysis. Our model indicates that the system consists of a B2.5 dwarf and a B9 giant of radii 3.2 and 3.7 R {sub ⊙}, respectively, orbiting in a circular orbit of radius 6.75 R {sub ⊙}. We also found M {sub c} = 1.7 ± 0.1 M {sub ⊙}, T {sub c} = 11,350 ± 100 K, and M {sub h} = 6.4 ± 0.1 M {sub ⊙}, T {sub h} = 20,000 ± 500 K, for the cooler and hotter star, respectively. We find broad single emission peaks in Hα and Hβ after subtracting the synthetic stellar spectra. Our results are consistent with mass exchange between the stars and suggest the existence of a stream of gas being accreted onto the early B-type star.

47 OTHER INSTRUMENTATION↗

Preliminary Model Comparison Results From the Sim-SEQ Project Using TOUGH2, STOMP, Eclipse, and VESA Approach

Sim-SEQ is an international initiative on model comparison for geologic carbon sequestration (GCS), with an objective to understand and, if possible, quantify model uncertainties. Model comparison efforts in Sim-SEQ are initially limited to one specific field test site, hereafter referred to as the Sim-SEQ Study site (or S-3 site). Within Sim-SEQ, different modeling teams are developing conceptual models of CO2 injection at the S-3 site. One of the conceptual models, developed by the LBNL team, is based on TOUGH2/EOS7C. In this paper, we present some preliminary model predictions of the S-3 site using the TOUGH2/EOS7C simulator. We also compare the predictions of the TOUGH2 simulator with three other conceptual models, developed by three different organizations, of the S-3 site.

carbon sequestration↗

Improving spot-scanning proton therapy patient specific quality assurance with HPlusQA, a second-check dose calculation engine

Purpose: The purpose of this study was to validate the use of HPlusQA, spot-scanning proton therapy (SSPT) dose calculation software developed at The University of Texas MD Anderson Cancer Center, as second-check dose calculation software for patient-specific quality assurance (PSQA). The authors also showed how HPlusQA can be used within the current PSQA framework.Methods: The authors compared the dose calculations of HPlusQA and the Eclipse treatment planning system with 106 planar dose measurements made as part of PSQA. To determine the relative performance and the degree of correlation between HPlusQA and Eclipse, the authors compared calculated with measured point doses. Then, to determine how well HPlusQA can predict when the comparisons between Eclipse calculations and the measured dose will exceed tolerance levels, the authors compared gamma index scores for HPlusQA versus Eclipse with those of measured doses versus Eclipse. The authors introduce the αβγ transformation as a way to more easily compare gamma scores.Results: The authors compared measured and calculated dose planes using the relative depth, z/R × 100%, where z is the depth of the measurement and R is the proton beam range. For relative depths than less than 80%, both Eclipse and HPlusQA calculations were within 2 cGy of dose measurements on average. When the relative depth was greater than 80%, the agreement between the calculations and measurements fell to 4 cGy. For relative depths less than 10%, the Eclipse and HPlusQA dose discrepancies showed a negative correlation, −0.21. Otherwise, the correlation between the dose discrepancies was positive and as large as 0.6. For the dose planes in this study, HPlusQA correctly predicted when Eclipse had and had not calculated the dose to within tolerance 92% and 79% of the time, respectively. In 4 of 106 cases, HPlusQA failed to predict when the comparison between measurement and Eclipse's calculation had exceeded the tolerance levels of 3% for dose and 3 mm for distance-to-agreement.Conclusions: The authors found HPlusQA to be reasonably effective (79%± 10%) in determining when the comparison between measured dose planes and the dose planes calculated by the Eclipse treatment planning system had exceeded the acceptable tolerance levels. When used as described in this study, HPlusQA can reduce the need for patient specific quality assurance measurements by 64%. The authors believe that the use of HPlusQA as a dose calculation second check can increase the efficiency and effectiveness of the QA process.

61 RADIATION PROTECTION AND DOSIMETRY↗

Constraints on the atmospheric circulation and variability of the eccentric hot Jupiter XO-3b

We report secondary eclipse photometry of the hot Jupiter XO-3b in the 4.5 μm band taken with the Infrared Array Camera on the Spitzer Space Telescope. We measure individual eclipse depths and center of eclipse times for a total of 12 secondary eclipses. We fit these data simultaneously with two transits observed in the same band in order to obtain a global best-fit secondary eclipse depth of 0.1580% ± 0.0036% and a center of eclipse phase of 0.67004 ± 0.00013. We assess the relative magnitude of variations in the dayside brightness of the planet by measuring the size of the residuals during ingress and egress from fitting the combined eclipse light curve with a uniform disk model and place an upper limit of 0.05%. The new secondary eclipse observations extend the total baseline from one and a half years to nearly three years, allowing us to place an upper limit on the periastron precession rate of 2.9 × 10{sup –3} deg day{sup –1}— the tightest constraint to date on the periastron precession rate of a hot Jupiter. We use the new transit observations to calculate improved estimates for the system properties, including an updated orbital ephemeris. We also use the large number of secondary eclipses to obtain the most stringent limits to date on the orbit-to-orbit variability of an eccentric hot Jupiter and demonstrate the consistency of multiple-epoch Spitzer observations.

79 ASTRONOMY AND ASTROPHYSICS↗

THE CHANGE OF THE ORBITAL PERIODS ACROSS ERUPTIONS AND THE EJECTED MASS FOR RECURRENT NOVAE CI AQUILAE AND U SCORPII

I report on the cumulative results from a program started 24 years ago designed to measure the orbital period change of recurrent novae (RNe) across an eruption. The goal is to use the orbital period change to measure the mass ejected during each eruption as the key part of trying to measure whether the RNe white dwarfs are gaining or losing mass over an entire eruption cycle, and hence whether they can be progenitors for Type Ia supernovae. This program has now been completed for two eclipsing RNe: CI Aquilae (CI Aql) across its eruption in 2000 and U Scorpii (U Sco) across its eruption in 1999. For CI Aql, I present 78 eclipse times from 1991 to 2009 (including four during the tail of the 2000 eruption) plus two eclipses from 1926 and 1935. For U Sco, I present 67 eclipse times, including 46 times during quiescence from 1989 to 2009, plus 21 eclipse times in the tails of the 1945, 1999, and 2010 eruptions. The eclipse times during the tails of eruptions are systematically and substantially shifted with respect to the ephemerides from the eclipses in quiescence, with this being caused by shifts of the center of light during the eruption. These eclipse times are plotted on an O - C diagram and fitted to models with a steady period change ( P-dot ) between eruptions (caused by, for example, conservative mass transfer) plus an abrupt period change ({Delta}P) at the time of eruption. The primary uncertainty arises from the correlation between {Delta}P with P-dot , such that a more negative P-dot makes for a more positive {Delta}P. For CI Aql, the best fit is {Delta}P = -3.7{sup +9.2}{sub -7.3} Multiplication-Sign 10{sup -7}. For U Sco, the best fit is {Delta}P = (+ 43 {+-} 69) Multiplication-Sign 10{sup -7} days. These period changes can directly give a dynamical measure of the mass ejected (M{sub ejecta}) during each eruption with negligible sensitivity to the stellar masses and no uncertainty from distances. For CI Aql, the 1{sigma} upper limit is M{sub ejecta} < 10 Multiplication-Sign 10{sup -7} M{sub Sun }. For U Sco, I derive M{sub ejecta} = (43 {+-} 67) Multiplication-Sign 10{sup -7} M{sub Sun }.

79 ASTRONOMY AND ASTROPHYSICS↗

IMRT Quality Assurance Using a Second Treatment Planning System

We used a second treatment planning system (TPS) for independent verification of the dose calculated by our primary TPS in the context of patient-specific quality assurance (QA) for intensity-modulated radiation therapy (IMRT). QA plans for 24 patients treated with inverse planned dynamic IMRT were generated using the Nomos Corvus TPS. The plans were calculated on a computed tomography scan of our QA phantom that consists of three Solid Water slabs sandwiching radiochromic films, and an ion chamber that is inserted into the center slab of the phantom. For the independent verification, the dose was recalculated using the Varian Eclipse TPS using the multileaf collimator files and beam geometry from the original plan. The data was then compared in terms of absolute dose to the ion chamber volume as well as relative dose on isodoses calculated at the film plane. The calculation results were also compared with measurements performed for each case. When comparing ion chamber doses, the mean ratio was 0.999 (SD 0.010) for Eclipse vs. Corvus, 0.988 (SD 0.020) for the ionization chamber measurements vs. Corvus, and 0.989 (SD 0.017) for the ionization chamber measurements vs. Eclipse. For 2D doses with gamma histogram, the mean value of the percentage of pixels passing the criteria of 3%, 3 mm was 94.4 (SD 5.3) for Eclipse vs. Corvus, 85.1 (SD 10.6) for Corvus vs. film, and 93.7 (SD 4.1) for Eclipse vs. film; and for the criteria of 5%, 3 mm, 98.7 (SD 1.5) for Eclipse vs. Corvus, 93.0 (SD 7.8) for Corvus vs. film, and 98.0 (SD 1.9) for Eclipse vs. film. We feel that the use of the Eclipse TPS as an independent, accurate, robust, and time-efficient method for patient-specific IMRT QA is feasible in clinic.

61 RADIATION PROTECTION AND DOSIMETRY↗

SU-E-T-165: Evaluation of Inhomogeneity Calculations for Electron Beams in Raystation Monte Carlo Algorithm

Purpose: To evaluate the accuracy of the Raystation electron Monte Carlo algorithm for bone and air inhomogeneity. Methods: A solid water phantom slab was drilled to contain two openings of 1.3cm diameter, 0.6cm apart. The center of the opening is at 1cm depth from the surface. Two Teflon rods of exact same diameter were inserted to investigate bone inhomogeneity. Slab is 2cm total in thickness and was placed on top of 10cm solid water. Plans were created in Raystation with clinical settings previously established for 6, 9, 12, 15 and 18MeV Elekta Infinity beams. Coronal profiles were extracted posteriorly to the inhomogeneity. EBT3 films were irradiated under the same conditions and analyzed using FilmQAPro using the red channel. Calibration films were used for all energies. Same plans and films were performed for a Varian accelerator with same energies and Eclipse Monte Carlo. Results: Air Inhomogeneities: For lower energies, Raystation- Film agreement is less than 1% for the regions of the air cavity. In the lateral interface border, Raystation underestimates dose by approximately 2%. Eclipse results are similar. For higher energies, Raystation-Film agreement remains the same across the air cavity and interface. Eclipse-Film difference increases with energy up to 5% for 18MeV, with Eclipse calculating higher doses than the film at the interface. Bone Inhomogeneities: For lower energies, Raystation underestimates the dose behind the bone up to 12%. Eclipse underestimates the dose in the same area up to 18%. For higher energies, the dose difference behind the bone decreases to 1% for Raystation and 3% for Eclipse. At the lateral interface, Raystation underestimates the dose by 2.2% and Eclipse underestimates the dose by 5%. Conclusion: Raystation prediction for air and bone is acceptable. Maximum deviations are consistent with algorithm limitations. Differences between calculations and measurement are closer for Raystation than for Eclipse.

60 APPLIED LIFE SCIENCES↗

SU-E-T-472: A Multi-Dimensional Measurements Comparison to Analyze a 3D Patient Specific QA Tool

Purpose: To quantitatively evaluate a 3D patient specific QA tool using 2D film and 3D Presage dosimetry. Methods: A brain IMRT case was delivered to Delta4, EBT2 film and Presage plastic dosimeter. The film was inserted in the solid water slabs at 7.5cm depth for measurement. The Presage dosimeter was inserted into a head phantom for 3D dose measurement. Delta4's Anatomy software was used to calculate the corresponding dose to the film in solid water slabs and to Presage in the head phantom. The results from Anatomy were compared to both calculated results from Eclipse and measured dose from film and Presage to evaluate its accuracy. Using RIT software, we compared the “Anatomy” dose to the EBT2 film measurement and the film measurement to ECLIPSE calculation. For 3D analysis, DICOM file of “Anatomy” was extracted and imported to CERR software, which was used to compare the Presage dose to both “Anatomy” calculation and ECLIPSE calculation. Gamma criteria of 3% - 3mm and 5% - 5mm was used for comparison. Results: Gamma passing rates of film vs “Anatomy”, “Anatomy” vs ECLIPSE and film vs ECLIPSE were 82.8%, 70.9% and 87.6% respectively when 3% - 3mm criteria is used. When the criteria is changed to 5% - 5mm, the passing rates became 87.8%, 76.3% and 90.8% respectively. For 3D analysis, Anatomy vs ECLIPSE showed gamma passing rate of 86.4% and 93.3% for 3% - 3mm and 5% - 5mm respectively. The rate is 77.0% for Presage vs ECLIPSE analysis. The Anatomy vs ECLIPSE were absolute dose comparison. However, film and Presage analysis were relative comparison Conclusion: The results show higher passing rate in 3D than 2D in “Anatomy” software. This could be due to the higher degrees of freedom in 3D than in 2D for gamma analysis.

60 APPLIED LIFE SCIENCES↗

SU-F-T-302: Implementation of the RadCalc Image Analysis Tool for IMRT QA

Purpose: To assess RadCalc as a means for analyzing fluence maps of IMRT QA patient plans. Eclipse generated fluence maps were compared to RadCalc fluence maps generated from both Eclipse parameters and from dynalog trajectory files. Methods: Six IMRT plans consisting of fifty individual fields were compared both field-by-field and as composite plans. These plans were exported from Eclipse to RadCalc. Each plan was then delivered in QA mode on a Varian Clinac iX, while recording and saving the dynalog trajectory files. These files were then imported into RadCalc, providing three sources of generating fluence maps: Eclipse, RadCalc, and dynalog files. Using the image analysis tool in RadCalc, a gamma analysis was then performed as a point-by-point comparison for each IMRT field. The Eclipse fluence map was used as the baseline for each comparison. Results: Based on the manufacturer’s recommendations, all fields were normalized to the maximum pixel value within each Eclipse field. All data was analyzed using a gamma index of 3mm/3% with passing criteria of 90%. For both dynalog analysis and RadCalc fluence analysis, 48/50 created fluence maps passed at greater than 90% when compared with the Eclipse baseline. In analyzing the composite of each of the six patients’ plans, all plans passed over 90%. Conclusion: Using the dynalog trajectory files in combination with RadCalc Version 6.3 image analysis is a promising metric for verifying IMRT QA passing rates. Notably, if a field failed, it did so for both dynalog and RadCalc compared to Eclipse. This suggests RadCalc can accurately simulate fluence maps, with similar results to dynalog comparisons. Limitations within the RadCalc software were discovered in the analytical process such as pixel resolution and the inability to set minimum threshold values. Comparisons could be extended to include dose map and distance to agreement analysis by expanding software capabilities.

60 APPLIED LIFE SCIENCES↗

WARM SPITZER OBSERVATIONS OF THREE HOT EXOPLANETS: XO-4b, HAT-P-6b, AND HAT-P-8b

We analyze Warm Spitzer/Infrared Array Camera observations of the secondary eclipses of three planets, XO-4b, HAT-P-6b, and HAT-P-8b. We measure secondary eclipse amplitudes at 3.6 {mu}m and 4.5 {mu}m for each target. XO-4b exhibits a stronger eclipse depth at 4.5 {mu}m than at 3.6 {mu}m, which is consistent with the presence of a temperature inversion. HAT-P-8b shows a stronger eclipse amplitude at 3.6 {mu}m and is best described by models without a temperature inversion. The eclipse depths of HAT-P-6b can be fitted with models with a small or no temperature inversion. We consider our results in the context of a postulated relationship between stellar activity and temperature inversion and a relationship between irradiation level and planet dayside temperature, as discussed by Knutson et al. and Cowan and Agol, respectively. Our results are consistent with these hypotheses, but do not significantly strengthen them. To measure accurate secondary eclipse central phases, we require accurate ephemerides. We obtain primary transit observations and supplement them with publicly available observations to update the orbital ephemerides of the three planets. Based on the secondary eclipse timing, we set upper boundaries for ecos ({omega}) for HAT-P-6b, HAT-P-8b, and XO-4b and find that the values are consistent with circular orbits.

79 ASTRONOMY AND ASTROPHYSICS↗

WARM SPITZER PHOTOMETRY OF THREE HOT JUPITERS: HAT-P-3b, HAT-P-4b AND HAT-P-12b

We present Warm Spitzer/IRAC secondary eclipse time series photometry of three short-period transiting exoplanets, HAT-P-3b, HAT-P-4b and HAT-P-12b, in both the available 3.6 and 4.5 {mu}m bands. HAT-P-3b and HAT-P-4b are Jupiter-mass objects orbiting an early K and an early G dwarf star, respectively. For HAT-P-3b we find eclipse depths of 0.112%+0.015%-0.030% (3.6 micron) and 0.094%+0.016%-0.009% (4.5 {mu}m). The HAT-P-4b values are 0.142%+0.014%-0.016% (3.6 micron) and 0.122%+0.012%-0.014% 4.5 {mu}m). The two planets' photometry is consistent with inefficient heat redistribution from their day to night sides (and low albedos), but it is inconclusive about possible temperature inversions in their atmospheres. HAT-P-12b is a Saturn-mass planet and is one of the coolest planets ever observed during secondary eclipse, along with the hot Neptune GJ 436b and the hot Saturn WASP-29b. We are able to place 3{sigma} upper limits on the secondary eclipse depth of HAT-P-12b in both wavelengths: <0.042% (3.6 {mu}m) and <0.085% (4.5 {mu}m). We discuss these results in the context of the Spitzer secondary eclipse measurements of GJ 436b and WASP-29b. It is possible that we do not detect the eclipses of HAT-P-12b due to high eccentricity, but find that weak planetary emission in these wavelengths is a more likely explanation. We place 3{sigma} upper limits on the |e cos {omega}| quantity (where e is eccentricity and {omega} is the argument of periapsis) for HAT-P-3b (<0.0081) and HAT-P-4b (<0.0042), based on the secondary eclipse timings.

79 ASTRONOMY AND ASTROPHYSICS↗

Use of a realistic breathing lung phantom to evaluate dose delivery errors

Purpose: To compare the effect of respiration-induced motion on delivered dose (the interplay effect) for different treatment techniques under realistic clinical conditions. Methods: A flexible resin tumor model was created using rapid prototyping techniques based on a computed tomography (CT) image of an actual tumor. Twenty micro-MOSFETs were inserted into the tumor model and the tumor model was inserted into an anthropomorphic breathing phantom. Phantom motion was programed using the motion trajectory of an actual patient. A four-dimensional CT image was obtained and several treatment plans were created using different treatment techniques and planning systems: Conformal (Eclipse), step-and-shoot intensity-modulated radiation therapy (IMRT) (Pinnacle), step-and-shoot IMRT (XiO), dynamic IMRT (Eclipse), complex dynamic IMRT (Eclipse), hybrid IMRT [60% conformal, 40% dynamic IMRT (Eclipse)], volume-modulated arc therapy (VMAT) [single-arc (Eclipse)], VMAT [double-arc (Eclipse)], and complex VMAT (Eclipse). The complex plans were created by artificially pushing the optimizer to give complex multileaf collimator sequences. Each IMRT field was irradiated five times and each VMAT field was irradiated ten times, with each irradiation starting at a random point in the respiratory cycle. The effect of fractionation was calculated by randomly summing the measured doses. The maximum deviation for each measurement point per fraction and the probability that 95% of the model tumor had dose deviations less than 2% and 5% were calculated as a function of the number of fractions. Tumor control probabilities for each treatment plan were calculated and compared. Results: After five fractions, measured dose deviations were less than 2% for more than 95% of measurement points within the tumor model for all plans, except the complex dynamic IMRT, step-and-shoot IMRT (XiO), complex VMAT, and single-arc VMAT plans. Reducing the dose rate of the complex IMRT plans from 600 to 200 MU/min reduced the dose deviations to less than 2%. Dose deviations were less than 5% after five fractions for all plans, except the complex single-arc VMAT plan. Conclusions: Rapid prototyping techniques can be used to create realistic tumor models. For most treatment techniques, the dose deviations averaged out after several fractions. Treatments with unusually complicated multileaf collimator sequences had larger dose deviations. For IMRT treat-ments, dose deviations can be reduced by reducing the dose rate. For VMAT treatments, using two arcs instead of one is effective for reducing dose deviations.

60 APPLIED LIFE SCIENCES↗

Evaluation of the accuracy of 3DVH software estimates of dose to virtual ion chamber and film in composite IMRT QA

Purpose: A novel patient-specific intensity modulated radiation therapy (IMRT) QA system, 3DVH software and mapcheck 2, purports to be able to use diode array-measured beam doses and the patient's DICOM RT plan, structure set, and dose files to predict the delivered 3D dose distribution in the patient for comparison to the treatment planning system (TPS) calculated doses. In this study, the composite dose to an ion chamber and film in phantom predicted by the 3DVH and mapcheck 2 system is compared to the actual measured chamber and film doses. If validated in this context, then 3DVH can be used to perform an equivalent dose analysis as that obtained with film dosimetry and ion chamber-based composite IMRT QA. This is important for those losing their ability to perform film dosimetry for true composite IMRT QA and provides a measure of confidence in the accuracy of 3DVH 3D dose calculations which may replace phantom-based IMRT QA. Methods: The dosimetric results from 15 consecutive patient-specific IMRT QA tests performed by composite field irradiation of ion chamber and EDR2 film in a solid water phantom were compared to the predicted doses for those virtual detectors based on the calculated 3D dose by the 3DVH software using mapcheck 2 measured doses of each beam within each plan. For each of the 15 cases, immediately after performing the ion chamber plus film measurements, the mapcheck 2 was used to measure the dose for each beam of the plan. The dose to the volume of the virtual ion chamber and the dose distribution in the plane of the virtual film calculated by the 3DVH software was extracted. The ratio of the measured to 3DVH or eclipse-predicted ion chamber doses was calculated. The same plane in the phantom measured using film and calculated with eclipse was exported from 3DVH and the 2D gamma metric was used to compare the relationship between the film doses and the eclipse or 3DVH predicted planar doses. Also, the 3D gamma value was calculated in the 3DVH software which compares the eclipse dose to the 3DVH predicted dose distribution. For the 2D and 3D gamma metrics, 2% dose and 2 mm distance to agreement (DTA) were used. In addition, a simple dose difference was performed using either a 2% or 3% dose difference tolerance. Results: The mean ratio {+-} standard deviation of the measured vs 3DVH or vs eclipse-predicted dose to the ion chamber was 1.013 {+-} 0.015 and 1.003 {+-} 0.012, respectively. For 3DVH vs eclipse, the mean percentage of pixels failing the 3D gamma metric was 1.2% {+-} 1.4% while the failure rate for the 2D gamma metric was 1.1% {+-} 0.9%. When either 3DVH or eclipse was compared to EDR2 film, the gamma failure rate was 2.3% {+-} 2.0% and 1.6% {+-} 1.7%, respectively. Mean dose difference failures were 9%-27% {+-} 5%-15% for 2 or 3% dose difference tolerances, depending on the combination of systems tested. No statistically significant differences were found for any of the planar dosimetric comparisons. Conclusions: 3DVH + mapcheck 2 predicts the same absolute dose, the percent of pixels failing the gamma metric, and the percent of pixels failing 2% or 3% dose difference tolerance tests as one would have obtained had one made measurements in solid water phantom using an ion chamber and coronal film instead of a diode array. This is also a necessary although not sufficient condition for validation of the accuracy of 3DVH predictions of the 3D dose using beam-by-beam measurements.

61 RADIATION PROTECTION AND DOSIMETRY↗

Validation of OSLD and a treatment planning system for surface dose determination in IMRT treatments

Purpose: To evaluate the accuracy of skin dose determination for composite multibeam 3D conformal radiation therapy (3DCRT) and intensity modulated radiation therapy (IMRT) treatments using optically stimulated luminescent dosimeters (OSLDs) and Eclipse treatment planning system. Methods: Surface doses measured by OSLDs in the buildup region for open field 6 MV beams, either perpendicular or oblique to the surface, were evaluated by comparing against dose measured by Markus Parallel Plate (PP) chamber, surface diodes, and calculated by Monte Carlo simulations. The accuracy of percent depth dose (PDD) calculation in the buildup region from the authors’ Eclipse system (Version 10), which was precisely commissioned in the buildup region and was used with 1 mm calculation grid, was also evaluated by comparing to PP chamber measurements and Monte Carlo simulations. Finally, an anthropomorphic pelvic phantom was CT scanned with OSLDs in place at three locations. A planning target volume (PTV) was defined that extended close to the surface. Both an 8 beam 3DCRT and IMRT plan were generated in Eclipse. OSLDs were placed at the CT scanned reference locations to measure the skin doses and were compared to diode measurements and Eclipse calculations. Efforts were made to ensure that the dose comparison was done at the effective measurement points of each detector and corresponding locations in CT images. Results: The depth of the effective measurement point is 0.8 mm for OSLD when used in the buildup region in a 6 MV beam and is 0.7 mm for the authors’ surface diode. OSLDs and Eclipse system both agree well with Monte Carlo and/or Markus PP ion chamber and/or diode in buildup regions in 6 MV beams with normal or oblique incidence and across different field sizes. For the multiple beam 3DCRT plan and IMRT plans, the differences between OSLDs and Eclipse calculations on the surface of the anthropomorphic phantom were within 3% and distance-to-agreement less than 0.3 mm. Conclusions: The authors’ experiment showed that OSLD is an accurate dosimeter for skin dose measurements in complex 3DCRT or IMRT plans. It also showed that an Eclipse system with accurate commissioning of the data in the buildup region and 1 mm calculation grid can calculate surface doses with high accuracy and has a potential to replacein vivo measurements.

60 APPLIED LIFE SCIENCES↗

EPSILON AURIGAE: AN IMPROVED SPECTROSCOPIC ORBITAL SOLUTION

A rare eclipse of the mysterious object {epsilon} Aurigae will occur in 2009-2011. We report an updated single-lined spectroscopic solution for the orbit of the primary star based on 20 years of monitoring at the CfA, combined with historical velocity observations dating back to 1897. There are 518 new CfA observations obtained between 1989 and 2009. Two solutions are presented. One uses the velocities outside the eclipse phases together with mid-times of previous eclipses, from photometry dating back to 1842, which provide the strongest constraint on the ephemeris. This yields a period of 9896.0 {+-} 1.6 days (27.0938 {+-} 0.0044 years) with a velocity semi-amplitude of 13.84 {+-} 0.23 km s{sup -1} and an eccentricity of 0.227 {+-} 0.011. The middle of the current ongoing eclipse predicted by this combined fit is JD 2,455,413.8 {+-} 4.8, corresponding to 2010 August 5. If we use only the radial velocities, we find that the predicted middle of the current eclipse is nine months earlier. This would imply that the gravitating companion is not the same as the eclipsing object. Alternatively, the purely spectroscopic solution may be biased by perturbations in the velocities due to the short-period oscillations of the supergiant.

79 ASTRONOMY AND ASTROPHYSICS↗

THE 8 {mu}m PHASE VARIATION OF THE HOT SATURN HD 149026b

We monitor the star HD 149026 and its Saturn-mass planet at 8.0 {mu}m over slightly more than half an orbit using the Infrared Array Camera on the Spitzer Space Telescope. We find an increase of 0.0227% +- 0.0066% (3.4sigma significance) in the combined planet-star flux during this interval. The minimum flux from the planet is 45% +- 19% of the maximum planet flux, corresponding to a difference in brightness temperature of 480 +- 140 K between the two hemispheres. We derive a new secondary eclipse depth of 0.0411% +- 0.0076% in this band, corresponding to a dayside brightness temperature of 1440 +- 150 K. Our new secondary eclipse depth is half that of a previous measurement (3.0sigma difference) in this same bandpass by Harrrington et al. We re-fit the Harrrington et al. data and obtain a comparably good fit with a smaller eclipse depth that is consistent with our new value. In contrast to earlier claims, our new eclipse depth suggests that this planet's dayside emission spectrum is relatively cool, with an 8 {mu}m brightness temperature that is less than the maximum planet-wide equilibrium temperature. We measure the interval between the transit and secondary eclipse and find that that the secondary eclipse occurs 20.9{sup +7.2}{sub -6.5} minutes earlier (2.9sigma) than predicted for a circular orbit, a marginally significant result. This corresponds to ecos(omega) = -0.0079{sup +0.0027}{sub -0.0025}, where e is the planet's orbital eccentricity and omega is the argument of pericenter.

79 ASTRONOMY AND ASTROPHYSICS↗